Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

Learn more about GLP-1 pills and how they may be more convenient and cost-effective than the injections.

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...

According to research published by the British Medical Journal (BMJ), those using weight-loss injection drugs could also regain weight almost four times faster than they would after dieting once they ...

In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking ...